Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
remifentanil + propofol + desflurane
- Development stage
- Phase 4
- Lead developer
- Abbott
- Modality
- Small Molecules
- Administration
- Intravenous, Inhalation
01
Overview
A balanced anesthesia combination used for induction and maintenance of general anesthesia during surgical procedures. This combination leverages remifentanil (an ultra-short-acting μ-opioid receptor agonist), propofol (an intravenous anesthetic), and desflurane (an inhalational anesthetic) to provide effective anesthesia with rapid recovery characteristics and hemodynamic stability.
02
Targets
GABA-B (Gamma-aminobutyric acid receptor type B)GRIA1 (AMPA receptor subunit GluA1)GLRA1 (Glycine receptor subunit Alpha-1)MOR (Mu opioid receptor)KCNA1 (Voltage-gated potassium channel subfamily A member 1)
Beyond the preview
Go deeper on remifentanil + propofol + desflurane.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on remifentanil + propofol + desflurane.